# Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

> **NCT01960023** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **NSABP Foundation Inc**

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Neratinib

## Key facts

- **NCT ID:** NCT01960023
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-10
- **Primary completion:** 2016-07-13
- **Final completion:** 2016-07-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This registry was planned to report on the Phase II portion of the study. NSABP decided not to proceed with the Phase II portion of the study.
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01960023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01960023, "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01960023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*